Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153245 | 0.85 | GAA (0.65) | KDM4EGAAL3MBTL1SIGMAR1SLC6A12 | |
| SCHEMBL6153444 | 0.85 | SIGMAR1 (0.55) | KDM4EGAAROCK2L3MBTL1SIGMAR1 | |
| SCHEMBL444689 | 0.84 | KDM4E (0.62) | KDM4EGAAROCK2SIGMAR1JAK2 | |
| Hydrochloric Acid SCHEMBL6154430 | 0.84 | SIGMAR1 (0.54) | KDM4EGAAROCK2L3MBTL1SIGMAR1 | |
| SCHEMBL6155356 | 0.81 | L3MBTL1 (0.58) | KDM4EGAAL3MBTL1SIGMAR1SLC6A12 | |
| SCHEMBL13419693 | 0.80 | KDM4E (0.74) | KDM4EGAAROCK2L3MBTL1SIGMAR1 | |
| SCHEMBL12279961 | 0.79 | JAK2 (0.61) | KDM4EGAAROCK2SIGMAR1JAK2 | |
| SCHEMBL6153502 | 0.77 | OPRK1 (0.59) | KDM4EGAASIGMAR1SLC6A12TMEM97 | |
| SCHEMBL6154543 | 0.77 | SLC6A12 (0.59) | ROCK2SIGMAR1JAK2JAK1TYK2 | |
| SCHEMBL6155299 | 0.77 | JAK2 (0.53) | ROCK2SIGMAR1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KDM4E 2017/4885GAA 2875/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.